{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:35:45Z","timestamp":1791207345200,"version":"4.1.0"},"reference-count":105,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T00:00:00Z","timestamp":1755648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    <jats:italic>TP53<\/jats:italic>\n                    mutations drive oncogenesis and therapeutic resistance in myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML), impairing p53-regulated functions such as apoptosis, immune surveillance, and genomic stability, leading to immune evasion and metabolic reprogramming. The tumor microenvironment in\n                    <jats:italic>TP53<\/jats:italic>\n                    -mutated MDS and AML fosters leukemic progression through cytokine dysregulation, altered metabolism, and immune suppression. Current therapies, including chemotherapy and hypomethylating agents, offer limited efficacy, resulting in poor overall survival rates for these high-risk patients. However, novel therapeutic approaches provide promising avenues, including MDM2 inhibitors, p53-reactivating agents, pathway-targeted inhibitors (Hedgehog, Wnt, NF-\u03baB), immune modulation (checkpoint inhibitors, CAR-T therapy), metabolic interventions (fatty acid metabolism, glycolysis), and gene-editing technologies (CRISPR\/Cas9, base editing). This review explores the mechanisms of immune dysfunction in\n                    <jats:italic>TP53<\/jats:italic>\n                    -mutated MDS and AML while highlighting emerging therapeutic strategies, emphasizing the integration of targeted, metabolic, and immune-modulating therapies as a transformative approach to improve patient outcomes.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2025.1655486","type":"journal-article","created":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:36:10Z","timestamp":1755668170000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["TP53-mutated MDS and AML: immune dysregulation, tumor microenvironment, and emerging therapeutic strategies"],"prefix":"10.3389","volume":"15","author":[{"given":"Marwah M.","family":"Albakri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.028","article-title":"Putting p53 in context","volume":"170","author":"Kastenhuber","year":"2017","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrc.2017.109","article-title":"Targeting mutant p53 for efficient cancer therapy","volume":"18","author":"Bykov","year":"2018","journal-title":"Nat Rev Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2017.174","article-title":"Mechanisms of transcriptional regulation by p53","volume":"25","author":"Sullivan","year":"2018","journal-title":"Cell Death Differ"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1148389","article-title":"The role of p53 in anti-tumor immunity and response to immunotherapy","volume":"10","author":"Carlsen","year":"2023","journal-title":"Front Mol Biosci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgu134","article-title":"Caught in the cross fire: p53 in inflammation","volume":"35","author":"Cooks","year":"2014","journal-title":"Carcinogenesis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/humu.23035","article-title":"TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data","volume":"37","author":"Bouaoun","year":"2016","journal-title":"Hum Mutat"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.04.037","article-title":"Blinded by the light: the growing complexity of p53","volume":"137","author":"Vousden","year":"2009","journal-title":"Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/358015a0","article-title":"Cancer. p53, guardian of the genome","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nrm2395","article-title":"Transcriptional control of human p53-regulated genes","volume":"9","author":"Riley","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(00)81871-1","article-title":"p53, the cellular gatekeeper for growth and division","volume":"88","author":"Levine","year":"1997","journal-title":"Cell"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.607670","article-title":"Mutant p53 gain-of-function: role in cancer development, progression, and therapeutic approaches","volume":"8","author":"Alvarado-Ortiz","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-02-0553","article-title":"MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy","volume":"106","author":"Kojima","year":"2005","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/humu.22552","article-title":"TP 53 mutations in human cancer: database reassessment and prospects for the next decade","volume":"35","author":"Leroy","year":"2014","journal-title":"Hum mutation"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nature12634","article-title":"Mutational landscape and significance across 12 major cancer types","volume":"502","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.205013","article-title":"Clinical implications of subclonal TP53 mutations in acute myeloid leukemia","volume":"104","author":"Prochazka","year":"2019","journal-title":"Haematologica"},{"key":"B17","doi-asserted-by":"publisher","first-page":"5649","DOI":"10.1038\/s41467-019-13542-2","article-title":"Mutant p53 drives clonal hematopoiesis through modulating epigenetic pathway","volume":"10","author":"Chen","year":"2019","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2272","article-title":"Acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations - A distinct stem cell disorder","volume":"26","author":"Sill","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03300-8","article-title":"Deletion of 17p in cancers: Guilt by (p53) association","volume":"44","author":"van Kampen","year":"2025","journal-title":"Oncogene"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-08-375758","article-title":"TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome","volume":"119","author":"Rucker","year":"2012","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006239","article-title":"TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS\/AML","volume":"6","author":"Weinberg","year":"2022","journal-title":"Blood advances"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM evidence"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"New Engl J Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood J Am Soc Hematology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.6004\/jnccn.2025.0013","article-title":"NCCN guidelines\u00ae Insights: myelodysplastic syndromes, version 2.2025: featured updates to the NCCN guidelines","volume":"23","author":"Greenberg","year":"2025","journal-title":"J Natl Compr Cancer Network"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003120","article-title":"Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia","volume":"4","author":"Short","year":"2020","journal-title":"Blood advances"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-02-832360","article-title":"Prognostic factors influencing survival after allogeneic transplantation for AML\/MDS patients with TP53 mutations","volume":"131","author":"Ciurea","year":"2018","journal-title":"Blood J Am Soc Hematology"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104310","article-title":"Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated myelodysplastic syndrome: A systematic review and meta-analysis","volume":"196","author":"Shahzad","year":"2024","journal-title":"Crit Rev oncology\/hematology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2018.05.019","article-title":"TP53 mutation as potential negative predictor for response of anti-CTLA-4 therapy in metastatic melanoma","volume":"32","author":"Xiao","year":"2018","journal-title":"EBioMedicine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2019.07.009","article-title":"Correlate the TP53 mutation and the HRAS mutation with immune signatures in head and neck squamous cell cancer","volume":"17","author":"Lyu","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/5952836","article-title":"TP53 mutations promote immunogenic activity in breast cancer","volume":"2019","author":"Liu","year":"2019","journal-title":"J Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.13483","article-title":"TP53 mutations, expression and interaction networks in human cancers","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.717527","article-title":"Association analyses of TP53 mutation with prognosis, tumor mutational burden, and immunological features in acute myeloid leukemia","volume":"12","author":"Wen","year":"2021","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1038\/ncomms3359","article-title":"p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1","volume":"4","author":"Wang","year":"2013","journal-title":"Nat Commun"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002512","article-title":"TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML","volume":"4","author":"Vadakekolathu","year":"2020","journal-title":"Blood Adv"},{"key":"B40","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41392-023-01559-5","article-title":"Hedgehog signaling in tissue homeostasis, cancers, and targeted therapies","volume":"8","author":"Jing","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI128644","article-title":"Hedgehog signaling promotes tumor-associated macrophage polarization to suppress intratumoral CD8+ T cell recruitment","volume":"129","author":"Petty","year":"2019","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","first-page":"6\u20136","DOI":"10.1172\/jci.insight.146707","article-title":"Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function","volume":"6","author":"Petty","year":"2021","journal-title":"JCI Insight"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/biom12030453","article-title":"Cross-talk between p53 and Wnt signaling in cancer","volume":"12","author":"Xiao","year":"2022","journal-title":"Biomolecules"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/cells8111403","article-title":"Wnt signalling in acute myeloid leukaemia","volume":"8","author":"Gruszka","year":"2019","journal-title":"Cells"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116154","article-title":"Wnt signaling: Modulating tumor-associated macrophages and related immunotherapeutic insights","volume":"223","author":"Yuan","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"jcs237453","DOI":"10.1242\/jcs.237453","article-title":"p53, cancer and the immune response","volume":"133","author":"Blagih","year":"2020","journal-title":"J Cell Sci"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31896","article-title":"The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2023-174871","article-title":"Spatially resolved transcriptomics unveils unique T-cell dysfunctional states and prognostic gene expression signatures in TP53-mutated acute myeloid leukemia","volume":"142","author":"Vadakekolathu","year":"2023","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4661","article-title":"Transcriptional profiling demonstrates altered characteristics of CD8(+) cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia","volume":"11","author":"Abolhalaj","year":"2022","journal-title":"Cancer Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-0332","article-title":"TP53-mutated myelodysplastic syndrome and acute myeloid leukemia: biology, current therapy, and future directions","volume":"12","author":"Daver","year":"2022","journal-title":"Cancer Discov"},{"key":"B51","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.1182\/blood-2024-205849","article-title":"Impact of TP53 mutation on outcome after allogeneic stem cell transplantation for patients with MDS\/AML not in complete remission","volume":"144","author":"Steiner","year":"2024","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100689","article-title":"Therapeutic strategies in low and high-risk MDS: What does the future have to offer","volume":"45","author":"Scalzulli","year":"2021","journal-title":"Blood Rev"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0481","article-title":"Results of the phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia","volume":"22","author":"Andreeff","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B54","volume-title":"A phase III Multicenter, Randomized, Open Label Study of APR-246 in Combination with Azacitidine Versus Azacitidine Alone for the Treatment of (Tumor Protein) TP53 Mutant Myelodysplastic Syndromes","year":"2021"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.3324\/haematol.2023.284346","article-title":"Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive post-remission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia","volume":"109","author":"Jaramillo","year":"2024","journal-title":"Haematologica"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-02001-z","article-title":"Glasdegib plus intensive or non-intensive chemotherapy for untreated acute myeloid leukemia: results from the randomized, phase 3 BRIGHT AML 1019 trial","volume":"37","author":"Sekeres","year":"2023","journal-title":"Leukemia"},{"key":"B57","doi-asserted-by":"publisher","first-page":"307","DOI":"10.3324\/haematol.2020.266155","article-title":"Targeting Wnt signaling in acute myeloid leukemia stem cells","volume":"107","author":"Pepe","year":"2021","journal-title":"Haematologica"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: A nonrandomized, open-label, phase II study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J Clin Oncol"},{"key":"B60","unstructured":"Study NCT04313881: Clinical Trial Information\n          \n          \n          \n          2025"},{"key":"B61","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/blood-2021-153638","article-title":"Phase I\/II study of azacitidine (AZA) with venetoclax (VEN) and magrolimab (Magro) in patients (pts) with newly diagnosed older\/unfit or high-risk acute myeloid leukemia (AML) and relapsed\/refractory (R\/R) AML","volume":"138","author":"Daver","year":"2021","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(23)01083-2","article-title":"AML-577 A phase III, randomized trial of magrolimab in combination with venetoclax and azacitidine in previously untreated patients with acute myeloid leukemia who are ineligible for intensive chemotherapy (ENHANCE-3)","volume":"23","author":"Daver","year":"2023","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1304336","article-title":"Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia","volume":"6","author":"Petersen","year":"2017","journal-title":"Oncoimmunology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170201","article-title":"Safety and anti-leukemic activity of CD123-CAR T cells in pediatric patients with AML: preliminary results from a phase 1 trial","volume":"140","author":"Naik","year":"2022","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-169928","article-title":"Ameli-01: a phase I trial of UCART123v1. 2, an anti-CD123 allogeneic CAR-T cell product, in adult patients with relapsed or refractory (R\/R) CD123+ acute myeloid leukemia (AML)","volume":"140","author":"Sallman","year":"2022","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1038\/s41467-021-26683-0","article-title":"Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia","volume":"12","author":"El Khawanky","year":"2021","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.1359.1359","article-title":"Treating relapsed\/refractory (RR) AML with biodegradable anti-CD123 CAR modified T cells","volume":"130","author":"Cummins","year":"2017","journal-title":"Blood"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-179667","article-title":"CD33 CAR T-cells (CD33CART) for children and young adults with relapsed\/refractory AML: dose-escalation results from a phase I\/II multicenter trial","volume":"142","author":"Shah","year":"2023","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002779","article-title":"Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia","volume":"135","author":"He","year":"2020","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.373","article-title":"Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen","volume":"31","author":"Rafiq","year":"2017","journal-title":"Leukemia"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.234","article-title":"CAR T cells for acute myeloid leukemia: the LeY of the land","volume":"21","author":"Brenner","year":"2013","journal-title":"Mol Ther"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06496-5","article-title":"Epitope editing enables targeted immunotherapy of acute myeloid leukaemia","volume":"621","author":"Casirati","year":"2023","journal-title":"Nature"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15194787","article-title":"Unraveling the anticancer potential of statins: mechanisms and clinical significance","volume":"15","author":"Zaky","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e35721","article-title":"Glycolysis and chemoresistance in acute myeloid leukemia","volume":"10","author":"Yang","year":"2024","journal-title":"Heliyon"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-020-0623-4","article-title":"Cas9 activates the p53 pathway and selects for p53-inactivating mutations","volume":"52","author":"Enache","year":"2020","journal-title":"Nat Genet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2018.01.014","article-title":"Restoring the p53 \u2018Guardian\u2019phenotype in p53-deficient tumor cells with CRISPR\/Cas9","volume":"36","author":"Chira","year":"2018","journal-title":"Trends Biotechnol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1021\/acssynbio.8b00202","article-title":"Synthesizing a genetic sensor based on CRISPR-cas9 for specifically killing p53-deficient cancer cells","volume":"7","author":"Zhan","year":"2018","journal-title":"ACS Synth Biol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaa053","article-title":"A statistical framework for predicting critical regions of p53-dependent enhancers","volume":"22","author":"Niu","year":"2021","journal-title":"Brief Bioinform"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt plus azacitidine after allogeneic hematopoietic stem-cell transplantation for TP53-mutant acute myeloid leukemia and myelodysplastic syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02342","article-title":"Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: A phase II study by the groupe francophone des myelodysplasies (GFM)","volume":"39","author":"Cluzeau","year":"2021","journal-title":"J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41419-018-0463-7","article-title":"APR-246 reactivates mutant p53 by targeting cysteines 124 and 277","volume":"9","author":"Zhang","year":"2018","journal-title":"Cell Death Dis"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13194888","article-title":"Hedgehog signaling in myeloid Malignancies","volume":"13","author":"Abraham","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S216628","article-title":"Suppressing Hedgehog signaling reverses drug resistance of refractory acute myeloid leukemia","volume":"12","author":"Huang","year":"2019","journal-title":"Onco Targets Ther"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718585","article-title":"GLI3 repressor determines Hedgehog pathway activation and is required for response to SMO antagonist glasdegib in AML","volume":"129","author":"Chaudhry","year":"2017","journal-title":"Blood J Am Soc Hematology"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2824","article-title":"Phase Ib study of glasdegib, a hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS","volume":"24","author":"Savona","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.960943","article-title":"The hedgehog pathway in hematopoiesis and hematological Malignancy","volume":"12","author":"Lemos","year":"2022","journal-title":"Front Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139752","article-title":"Blast MRD AML-2: blockade of PD-1 added to standard therapy to target measurable residual disease (MDR) in acute myeloid leukemia (AML) 2-a randomized phase 2 study of the venetoclax, azacitidine, and pembrolizumab versus venetoclax and azacitidine as first line therapy in older patients with AML who are ineligible or who refuse intensive chemotherapy","volume":"136","author":"Zeidan","year":"2020","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006138","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Advances"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005487","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Advances"},{"key":"B92","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12935-023-02902-0","article-title":"Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired","volume":"23","author":"Marei","year":"2023","journal-title":"Cancer Cell Int"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.1182\/blood-2023-180500","article-title":"CAR T-cell therapy combined with PD-1 inhibitors significantly improve the efficacy and prognosis of r\/r DLBCL with TP53 alterations","volume":"142","author":"Xue","year":"2023","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","first-page":"4299","DOI":"10.1182\/blood-2024-208170","article-title":"VIP expression drives an immunosuppressive tumor microenvironment in TP53-mutated AML","volume":"144","author":"Zeng","year":"2024","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40164-024-00490-x","article-title":"Challenges and strategies associated with CAR-T cell therapy in blood Malignancies","volume":"13","author":"Liu","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091358","article-title":"CD123 as a therapeutic target in the treatment of hematological Malignancies","volume":"11","author":"Testa","year":"2019","journal-title":"Cancers"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01232-2","article-title":"Autologous CD33-CAR-T cells for treatment of relapsed\/refractory acute myelogenous leukemia","volume":"35","author":"Tambaro","year":"2021","journal-title":"Leukemia"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.656218","article-title":"Immunotherapy in acute myeloid leukemia: where we stand","volume":"11","author":"Isidori","year":"2021","journal-title":"Front Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.06.008","article-title":"In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8","volume":"29","author":"Ryningen","year":"2005","journal-title":"Leukemia Res"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2019.106180","article-title":"Interleukin-8 blockade prevents activated endothelial cell mediated proliferation and chemoresistance of acute myeloid leukemia","volume":"84","author":"Vijay","year":"2019","journal-title":"Leuk Res"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1182\/blood-2024-201311","article-title":"Multi-omic analyses of TP53-mutated acute myeloid leukemia identify prognostic metabolic signatures","volume":"144","author":"Vadakekolathu","year":"2024","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12944-022-01687-x","article-title":"A novel fatty acid metabolism-related signature identifies features of the tumor microenvironment and predicts clinical outcome in acute myeloid leukemia","volume":"21","author":"Zhang","year":"2022","journal-title":"Lipids Health Dis"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1182\/blood-2023-185567","article-title":"TP53 deficiency in AML confers resistance to CAR T-cells that can be overcome by targeting the cholesterol or Wnt pathways","volume":"142","author":"Mueller","year":"2023","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.120650","article-title":"Introduction of mutant TP53 related genes in metabolic pathways and evaluation their correlation with immune cells, drug resistance and sensitivity","volume":"303","author":"Motlagh","year":"2022","journal-title":"Life Sci"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiomed.2023.107078","article-title":"Characterization of the metabolic alteration-modulated tumor microenvironment mediated by TP53 mutation and hypoxia","volume":"163","author":"Luo","year":"2023","journal-title":"Comput Biol Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1655486\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,20]],"date-time":"2025-08-20T05:36:13Z","timestamp":1755668173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1655486\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,20]]},"references-count":105,"alternative-id":["10.3389\/fonc.2025.1655486"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1655486","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,20]]},"article-number":"1655486"}}